NLM Digital Collections

Search

Start Over Subjects Medicare Part D -- economics ✖Remove constraint Subjects: Medicare Part D -- economics

52. Catastrophic coverage in the Medicare Part D drug benefit: which beneficiaries need it and how much are they spending?

Author(s):
Sen, Aditi P., author
Parasrampuria, Sonal, author
Anderson, Kelly E., author
Anderson, Gerard, author
Publication:
[New York, N.Y.] : The Commonwealth Fund, September 2020
Subject(s):
Health Expenditures -- statistics & numerical data
Medicare Part D -- economics
Financing, Personal
United States

53. Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use

Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, March 2022
Subject(s):
Biosimilar Pharmaceuticals
Drug Costs -- legislation & jurisprudence
Government Regulation
Medicare Part D -- economics
United States
United States. Department of Health and Human Services
Centers for Medicare & Medicaid Services (U.S.)

54. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):
Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):
Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)

55. Do states adjust Medicaid enrollment in response to capitation rates?: evidence from the Medicare Part D clawback

Author(s):
Quinby, Laura D., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, June 2019
Subject(s):
Capitation Fee
Dual MEDICAID MEDICARE Eligibility
Medicaid -- economics
Medicare -- economics
Medicare Part D -- economics
Federal Government
Forecasting
Health Expenditures -- trends
State Government
Humans
United States

56. Payment reform

Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Health Care Reform -- economics
Health Care Reform -- legislation & jurisprudence
Insurance, Health, Reimbursement -- legislation & jurisprudence
Emergency Medical Services -- economics
Federal Government
Home Care Services -- economics
Medicare Part D -- economics
Medical Oncology -- economics
Patient Readmission
Prenatal Care -- economics
Reimbursement Mechanisms
Social Determinants of Health
State Government
Transportation of Patients
Value-Based Purchasing
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

57. Cost savings

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Cost Control -- legislation & jurisprudence
Cost Savings
Drug Costs -- legislation & jurisprudence
Economics, Pharmaceutical
Legislation, Drug
Access to Information
Biosimilar Pharmaceuticals
Commerce
Conflict of Interest
Drug Industry
Insurance, Pharmaceutical Services
Managed Care Programs
Medicaid -- economics
Medicare Part D -- economics
Patents as Topic
State Government
Humans
United States

58. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

59. Part D plans generally include drugs commonly used by dual eligibles: 2019

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2019
Subject(s):
Dual MEDICAID MEDICARE Eligibility
Formularies as Topic
Insurance Coverage
Medicare Part D -- economics
Insurance, Pharmaceutical Services -- economics
Medicaid -- economics
Medicare -- economics
Humans
United States
United States.
Centers for Medicare & Medicaid Services (U.S.)

60. Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 2015

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2019
Subject(s):
Drug Costs -- statistics & numerical data
Drug Costs -- trends
Insurance, Health, Reimbursement -- statistics & numerical data
Insurance, Health, Reimbursement -- trends
Medicare Part D -- economics
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Economics, Pharmaceutical -- statistics & numerical data
Economics, Pharmaceutical -- trends
Forecasting
Prescription Drugs -- economics
Humans
United States